Baseline characteristics of the patient population
| Variable . | Frequency (N = 1300) . |
|---|---|
| Male sex, n (%) | 773 (59.5) |
| Race, n (%) | |
| White | 964 (74.2) |
| Black | 99 (7.6) |
| Asian | 71 (5.5) |
| Other | 166 (12.7) |
| Ethnicity, n (%) | |
| Hispanic/Latino | 216 (16.6) |
| Non-Hispanic/Latino | 1031 (79.3) |
| Unknown | 53 (4.1) |
| Disease category, n (%) | |
| ALL | 164 (12.6) |
| AML/MDS | 765 (58.8) |
| Aplastic anemia | 21 (1.6) |
| CLL | 52 (4.0) |
| CML/MPD | 158 (12.2) |
| Hodgkin lymphoma | 19 (1.5) |
| Other lymphoma | 91 (7.0) |
| Multiple myeloma | 25 (1.9) |
| Sarcoma | 2 (0.2) |
| Other hematologic malignancies | 3 (0.2) |
| Donor type, n (%) | |
| Matched related | 452 (34.8) |
| Matched unrelated | 674 (51.8) |
| Mismatched related | 174 (13.4) |
| Mean age ± SD, y | 50.8 ± 15.4 |
| Mean BMI ± SD, kg/m2 | 28.1 ± 6.3 |
| Mean Karnofsky score ± SD | 86.5 ± 9.4 |
| Variable . | Frequency (N = 1300) . |
|---|---|
| Male sex, n (%) | 773 (59.5) |
| Race, n (%) | |
| White | 964 (74.2) |
| Black | 99 (7.6) |
| Asian | 71 (5.5) |
| Other | 166 (12.7) |
| Ethnicity, n (%) | |
| Hispanic/Latino | 216 (16.6) |
| Non-Hispanic/Latino | 1031 (79.3) |
| Unknown | 53 (4.1) |
| Disease category, n (%) | |
| ALL | 164 (12.6) |
| AML/MDS | 765 (58.8) |
| Aplastic anemia | 21 (1.6) |
| CLL | 52 (4.0) |
| CML/MPD | 158 (12.2) |
| Hodgkin lymphoma | 19 (1.5) |
| Other lymphoma | 91 (7.0) |
| Multiple myeloma | 25 (1.9) |
| Sarcoma | 2 (0.2) |
| Other hematologic malignancies | 3 (0.2) |
| Donor type, n (%) | |
| Matched related | 452 (34.8) |
| Matched unrelated | 674 (51.8) |
| Mismatched related | 174 (13.4) |
| Mean age ± SD, y | 50.8 ± 15.4 |
| Mean BMI ± SD, kg/m2 | 28.1 ± 6.3 |
| Mean Karnofsky score ± SD | 86.5 ± 9.4 |
ALL, acute lymphocytic leukemia; AML, acute myeloid leukemia; BMI, body mass index; CLL, chronic lymphocytic leukemia; CML, chronic myeloid leukemia; MDS, myelodysplastic syndrome; MPD, myeloproliferative disorder; SD, standard deviation.